If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
(13) Based on 266,016,298 shares of common stock issued and outstanding as of March 3, 2026, as confirmed by the Company's transfer agent on such date.


SCHEDULE 13D




Comment for Type of Reporting Person:
(8)(10)(11) Includes 3,000 shares of common stock held by Dr. Kukes' spouse. (13) Based on 266,016,298 shares of common stock issued and outstanding as of March 3, 2026, as confirmed by the Company's transfer agent on such date.


SCHEDULE 13D


 
SGK 2018 REVOCABLE TRUST
 
Signature:/s/ Dr. Simon G. Kukes
Name/Title:Dr. Simon G. Kukes, Trustee
Date:03/03/2026
 
KUKES SIMON G
 
Signature:/s/ Dr. Simon G. Kukes
Name/Title:Dr. Simon G. Kukes
Date:03/03/2026